The diagnostic value of urinary cytology versus dna methylation urine biomarker test for surveillance of non-muscle invasive bladder cancer

You have accessJournal of UrologyCME1 Apr 2023MP63-10 THE DIAGNOSTIC VALUE OF URINARY CYTOLOGY VERSUS DNA METHYLATION URINE BIOMARKER TEST FOR SURVEILLANCE OF NON-MUSCLE INVASIVE BLADDER CANCER Seyedeh Sanam Ladi Seyedian, Margot Van Den Sigtenhorst Fijlstra, Sina Sobhani, Sidney Roberts, Natalie Liu, Andrew Udov, Farshad Sheybaee Moghadam, Alireza Ghoreifi, Paolo Piatti, Benjamin Jara, Lucy Sanossian, Hooman Djaladat, Anne Schuckman, Gangning Liang, and Siamak Daneshmand Seyedeh Sanam Ladi SeyedianSeyedeh Sanam Ladi Seyedian More articles by this author , Margot Van Den Sigtenhorst FijlstraMargot Van Den Sigtenhorst Fijlstra More articles by this author , Sina SobhaniSina Sobhani More articles by this author , Sidney RobertsSidney Roberts More articles by this author , Natalie LiuNatalie Liu More articles by this author , Andrew UdovAndrew Udov More articles by this author , Farshad Sheybaee MoghadamFarshad Sheybaee Moghadam More articles by this author , Alireza GhoreifiAlireza Ghoreifi More articles by this author , Paolo PiattiPaolo Piatti More articles by this author , Benjamin JaraBenjamin Jara More articles by this author , Lucy SanossianLucy Sanossian More articles by this author , Hooman DjaladatHooman Djaladat More articles by this author , Anne SchuckmanAnne Schuckman More articles by this author , Gangning LiangGangning Liang More articles by this author , and Siamak DaneshmandSiamak Daneshmand More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003321.10AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Bladder cancer (BC) has a variable clinical course. With frequent recurrence, cystoscopy and urine cytology are routinely employed during follow-up of patients with a history of non-muscle invasive bladder cancer (NMIBC). Although there are multiple FDA approved urine-based tests for BC detection and surveillance, diagnostic accuracy of these urine-based assays is still suboptimal. Here, we compare the diagnostic value of urine cytology and a newly developed urine-based DNA methylation test for surveillance of NMIBC. METHODS: We included patients undergoing blue-light surveillance cystoscopy for NMIBC between February 2019 and September 2021. Urine samples were collected at each surveillance cystoscopy. Samples were analyzed with Bladder CARE, a urine-based assay that measures methylation levels of 3 bladder cancer specific biomarkers (TRNA-Cys, SIM2, and NKX1-1) and two internal control loci using methylation-sensitive restriction enzymes coupled with qPCR. Results are reported as Bladder CARE Index (BCI) score and categorized as “positive” (BCI>5), “high risk” (2.5更多